ADOPT: Airways Disease-Optimisation of Pharmaco-Therapy in lung cancer

Not Applicable

Completed

• Conditions: ung cancer, Chronic obstructive pulmonary disease (COPD); Respiratory; Other chronic obstructive pulmonary disease (COPD)

• Registration Number: ISRCTN12205188
• Lead Sponsor: The Royal Marsden NHS Foundation Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-02-28
• Study Completion: 2016-09-30
• Last Update Posted: 24 September 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

1. Male or female, age > 35 years
2. Diagnosis of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) or mesothelioma
3. Diagnosis of COPD
4. Subjective dyspnoea of visual analogue score (VAS) = 4

Exclusion Criteria

1. Involvement in any other studies of breathlessness
2. Reversible causes of breathlessness
3. Patients receiving radiotherapy, chemotherapy, biological therapy or surgery. Or a plan to commence these treatments within 4 weeks
4. Current use of bronchodilators either inhaled or oral (aminophyline, methyxanthines) except for short-acting bronchodilators
5. Recent change to oral corticosteroid therapy dose (within 1 week of randomisation)
6. Current use of beta-blockers for any reason
7. Current use of anti-cholinergic containing drugs
8. Current use of potent CYP30 inhibitors (ritonavir, ketoconazole, itraconazole)
9. Patients with the following conditions:
9.1. Asthma
9.2. Severe cardiovascular disorders (myocardial infarction within 6 week)
9.3. Heart rhythm abnormalities
9.4. Thyrotoxicosis
9.5. Uncorrected hypokalaemia
9.6. Glaucoma
9.7. Prostate problems
9.8. Patients with difficulty passing urine
9.9. Renal failure
9.10. TB (current or previous)
10. Pregnancy
11. Patients with hypersensitivity to any of the study drugs, lactose allergy

Study & Design

• Study Type: Interventional
• Study Design: Not specified